Novel UCL developed cancer drug to be trialled in humans

Patients with a number of Non-Hodgkin lymphoma (NHL) subtypes will be used to trial a novel cancer treatment developed by researchers at UCL, which holds "great promise" for several incurable conditions. A first-in-human trial investigating a novel cancer treatment, developed by researchers at UCL, will begin in patients with several Non-Hodgkin lymphoma (NHL) subtypes. Researchers at the NIHR UCLH Clinical Research Facility will lead the trial of the drug, called NVG-111, which was conceived and developed by Amit Nathwani, a Professor of Immunology at UCL Institute of Immunity & Transplantation. The drug will be trialled on patients with NHL subtypes, including relapsed/refractory chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). This multi-centre trial, sponsored and funded by NovalGen Limited, a UCL spinout company, will be taking place at various centres in the UK including UCLH. Professor Nathwani, who is also founder and Chief Executive of NovalGen, said: " The dosing of our first patient marks a significant milestone for NovalGen. "NVG-111 is our first clinical programme for patients with chronic lymphocytic leukemia and mantle cell lymphoma.